<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657136</url>
  </required_header>
  <id_info>
    <org_study_id>Casilino0001</org_study_id>
    <secondary_id>0001</secondary_id>
    <nct_id>NCT01657136</nct_id>
  </id_info>
  <brief_title>Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia</brief_title>
  <acronym>CIBIST</acronym>
  <official_title>Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinico Casilino ASL RMB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Policlinico Casilino ASL RMB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prospectively compare the effectiveness and safety of ivabradine
      and beta-blockers in the treatment of inappropriate sinus tachycardia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inappropriate sinus tachycardia (IST) is a non-paroxysmal arrhythmia, characterized by a
      persistently high sinus heart rate (HR) and/or an exaggerated HR response to minimal
      exertion, and can be responsible for palpitations, asthenia, chest pain, dizziness and
      syncope, which can be highly invalidating. Conventional treatment of IST, targeted to
      symptoms control, mainly consists on β-blockers. However, these drugs are often insufficient
      or not well tolerated because of side effects (mostly hypotension) that usually limit the
      administered dose. Ivabradine, a sinus rate lowering agent currently employed in Europe in
      the treatment of stable angina and chronic heart failure, has recently been demonstrated to
      be effective and safe in the treatment of IST by a few case reports and clinical trials. A
      randomized clinical trial comparing ivabradine to β-blockers has not be performed yet.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>heart rate reduction</measure>
    <time_frame>three months</time_frame>
    <description>Percentage of HR reduction at Holter ECG (mean, minimal and maximal)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate reduction</measure>
    <time_frame>three months</time_frame>
    <description>Percentage of maximal HR reduction at stress-test ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>physical tolerance and quality of life</measure>
    <time_frame>three months</time_frame>
    <description>Improvement of stress-tolerance (maximal load reached at stress test ECG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical tolerance and quality of life</measure>
    <time_frame>three months</time_frame>
    <description>Improvement of the quality of life (Minnesota QoL questionnaire)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Inappropriate Sinus Tachycardia</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivabradine will be initiated at a dose of 5 mg twice daily. Dosage should be augmented up to 7.5 mg twice daily in case of symptoms persistence and/or HR &gt; 85 bpm at rest ECG and eventually lowered up to 2.5 mg twice daily in the presence of side effects (phosphenes, diplopia and symptomatic bradycardia).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Beta blocker (Bisoprololo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bisoprololo will be initiated at a single dose of 5 mg daily. Dosage should be augmented up to 10 mg single dose daily in case of symptoms persistence and/or HR &gt; 85 bpm at rest ECG and eventually lowered up to 2,5 mg single dose daily in the presence of side effects (symptomatic bradycardia, hypotension).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>comparison of different drugs</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta blocker</intervention_name>
    <description>comparison of different drugs</description>
    <arm_group_label>Beta blocker (Bisoprololo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inappropriate sinus tachycardia (HR &gt;100 bpm at rest ECG and/or medium Holter ECG HR
             &gt;90 bpm)

          -  Age &gt; 18 years;

        Exclusion Criteria:

          -  Secondary causes of sinus tachycardia;

          -  Structural heart diseases,

          -  Postural orthostatic tachycardia syndrome;

          -  Sinus nodal reentrant tachycardia;

          -  Contraindications to beta-blockers;

          -  Administration of beta-blockers, non-di-hydropiridinic calcium channels antagonists,
             class I and III anti-arrhythmic drugs or digitalis at the time of enrollment;

          -  Age &lt; 18 years;

          -  Inability of giving informed consent;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonardo Calò, FESC MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Casilino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinico Casilino</name>
      <address>
        <city>Rome</city>
        <zip>00169</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Calò L, Rebecchi M, Sette A, Martino A, de Ruvo E, Sciarra L, De Luca L, Zuccaro LM, Giunta G, Ciccaglioni A, Lioy E, Fedele F. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm. 2010 Sep;7(9):1318-23. doi: 10.1016/j.hrthm.2010.05.034. Epub 2010 Jun 1.</citation>
    <PMID>20621618</PMID>
  </reference>
  <reference>
    <citation>Ptaszynski P, Kaczmarek K, Ruta J, Klingenheben T, Wranicz JK. Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy. Europace. 2013 Jan;15(1):116-21. doi: 10.1093/europace/eus204. Epub 2012 Jul 6.</citation>
    <PMID>22772053</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinico Casilino ASL RMB</investigator_affiliation>
    <investigator_full_name>Leonardo Calo</investigator_full_name>
    <investigator_title>Director of clinical arrhythmology and cardiac electrophysiology department</investigator_title>
  </responsible_party>
  <keyword>Inappropriate sinus tachycardia</keyword>
  <keyword>ivabradine</keyword>
  <keyword>beta blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Sinus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

